BIOLARGO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
August 05, 2022 at 11:35 am EDT
Share
Item 7.01 Regulation FD Disclosure.
On August 3, 2022, BioLargo, Inc. published the press release which is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit
99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained in this Item 7.01 and in the press
release attached as Exhibit 99.1 to this Current Report shall not be
incorporated by reference into any filing with the SEC made by the Company,
whether made before or after the date hereof, regardless of any general
incorporation language in such filing. The Company undertakes no duty or
obligation to update or revise the information contained in this report,
although it may do so from time to time as its management believes is
appropriate. Any such updating may be made through the filing of other reports
or documents with the SEC, through press releases or through other public
disclosures. For important information about forward looking statements, see the
information under the heading "Safe Harbor Act" in Exhibit 99.1 attached hereto.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release
104 Cover Page Interactive Data File (embedded within the Inline XBRL
BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. The Company invents, develops, and commercializes platform technologies to solve challenging environmental problems like polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. The Companyâs segments include ONM Environmental, which manufactures and sells its odor and VOC control products and services, including its flagship product, CupriDyne Clean; BLEST, which provides professional engineering services supporting its internal business units; Clyra Medical, which develops and sells medical products based on its technology; BioLargo Canada, which is primary engaged in research and development activities; and Corporate Operations, which support the operating segments with legal, accounting, human resources, and other services.
BIOLARGO, INC. 
